The U.S. Food and Drug Administration approved the first mRNA-based seasonal influenza vaccine on Aug. 5, 2026, for adults aged 50 and older, citing greater protection than standard flu shots.
The decision underscores the momentum of messenger RNA technology after the COVID-19 vaccines demonstrated that a single manufacturing platform can be rapidly reprogrammed for new targets.
Unlike traditional vaccines, which require tailored production for each pathogen, mRNA drugs are synthesized from interchangeable DNA templates, giving them predictable delivery, immune profile and degradation across candidates.
However, therapeutic mRNA lasts only about one day in cells, making the platform naturally suited to brief exposures such as vaccines rather than chronic therapies that need sustained protein production.
A second constraint is innate immune activation: mRNA delivered via lipid nanoparticles enters cells through endosomes, where pattern-recognition receptors treat it as viral RNA and trigger inflammation.
Chemically modifying uridine to pseudouridine or N1-methylpseudouridine — a breakthrough recognized with the 2023 Nobel Prize — largely prevents this response, and both COVID-19 vaccines use the technique.
Residual double-stranded RNA, a byproduct of in vitro transcription, can also provoke immunity; while it may boost vaccine efficacy, it is a liability for non-vaccine applications that require cleaner products.
Researchers are now pursuing computational sequence optimization to extend mRNA half-life and engineered RNA polymerases that generate fewer immunostimulatory byproducts, aiming to expand mRNA therapeutics into gene editing and protein replacement.
First mRNA flu shot approved by FDA bodes well for improving drugs of the future – though a few hurdles remain before mRNA can move beyond vaccines
This is an independent summary. The complete reporting, supporting context and any primary documents remain with The Conversation.